BCIQ Profiles

Company Profile ReportTarget Profile Report

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

Probiodrug AG (Euronext:PBD) reported data from the Phase IIa SAPHIR trial in 120 patients with early Alzheimer's disease (AD) showing that there was no significant difference between

Read the full 279 word article

How to gain access

Continue reading with a
two-week free trial.